14:57 , Jun 29, 2018 |  BC Week In Review  |  Company News

AbbVie, Calibr to develop universal CAR T therapies

AbbVie Inc. (NYSE:ABBV) and the California Institute for Biomedical Research (La Jolla, Calif.) partnered to develop universal CAR T therapies using the non-profit's switchable CAR T technology to treat hematological and solid tumors. AbbVie will pay...
00:07 , Mar 9, 2018 |  BioCentury  |  Finance

CAR T confidence

The first CAR T therapy approvals in the U.S. followed by CFDA guidelines on cell therapy development and manufacturing gave a boost to Chinese investor interest in the space, enabling JW Therapeutics (Shanghai) Co. Ltd....
05:42 , Jan 27, 2018 |  BioCentury  |  Strategy

Jump-starting growth

Celgene Corp.’s two deals this month -- including its largest ever acquisition, of Juno Therapeutics Inc. -- will help fill in the holes left by late-stage failures and commercial disappointments of candidates that were intended...
00:54 , Aug 9, 2017 |  BC Extra  |  Company News

Kite's CAR T to skip advisory committee

On a conference call to discuss its 2Q17 earnings, Kite Pharma Inc. (NASDAQ:KITE) said FDA has informed the company that it will not schedule an advisory committee meeting to discuss a BLA for axicabtagene ciloleucel...
21:15 , Jul 31, 2017 |  BC Extra  |  Company News

Kite submits MAA for CAR T therapy

Kite Pharma Inc. (NASDAQ:KITE) submitted an MAA to EMA for chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (KTE-C19) to treat relapsed or refractory diffuse large B cell lymphoma (DLBCL), transformed follicular lymphoma and...
00:34 , Jun 8, 2017 |  BC Extra  |  Clinical News

Novartis reports response data for CAR T in DLBCL

Novartis AG (NYSE:NVS; SIX:NOVN) said chimeric antigen receptor (CAR) T cell therapy tisagenlecleucel-T (CTL019) led to a best overall response rate (ORR) of 59% in the pivotal Phase II JULIET trial to treat relapsed or...
21:56 , Dec 2, 2016 |  BioCentury  |  Product Development

CNS CAR crash?

Juno Therapeutics Inc. and other investigators in the CAR T field don’t know what caused fatal neurotoxicity in the Phase II ROCKET trial of CAR therapy JCAR015. But it appears the study’s CNS disease exclusion...
07:00 , May 5, 2016 |  BC Innovations  |  Product R&D

Cell therapy's yada yada yada

The novel science and dramatic clinical results behind chimeric antigen receptor (CAR) T cells and other cell therapies have the technology labeled by many as one of the most promising advances in biotech. But away...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Clinical News

CAR T cell therapy targeting CD19: Phase I started

Ziopharm began an open-label, U.S. Phase I trial to evaluate IV CAR T cell therapy targeting CD19 over 1-2 days in about 30 patients. Ziopharm has exclusive, worldwide rights to the human in vivo effector...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Clinical News

CAR T cell therapy targeting CD19: Clinical trial data

Data from a clinical trial in patients with advanced CD19-positive malignancies after hematopoietic stem cell transplantation (HSCT) showed that 7 patients with advanced non-Hodgkin’s lymphoma (NHL) treated with Ziopharm’s CAR T therapy targeting CD19 using...